Commercial PA Criteria

Effective: October 13, 2023

Prior Authorization: Ojjaara (momelotinib)

Products Affected: Ojjaara (momelotinib) oral tablets

Medication Description: OJJAARA is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia

Covered Uses: Treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia

Exclusion Criteria: None

Required Medical Information:

1. Diagnosis

Prescriber Restriction: Prescribed by, or in consultation with, a hematologist or oncologist.

Age Restriction: 18 years of age or older

Coverage Duration: 12 months

Other Criteria:

Initial Approval Criteria

1. Myelofibrosis.

Note: Examples of myelofibrosis include primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.

A. Patient is ≥ 18 years of age; **AND**

B. Patient has intermediate-risk or high-risk disease; **AND**

C. Patient has anemia, defined as hemoglobin < 10 g/dL.

Renewal Criteria:

A. Member has responded positively to the treatment as determined by the prescribing physician; **AND**

B. Member has not experienced unacceptable toxicity from the drug.

References:

1. Product Information: OJJAARA oral tablets, momelotinib oral route. GlaxoSmithKline (per FDA), Durham, NC, 2023.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	10/13/2023